It's open season for Mylan's EpiPen as Sanofi, Teva stumble

Last week, Sanofi ($SNY) pulled the main competitor to Mylan's ($MYL) EpiPen--Auvi-Q--from the market on concerns that the pens might be delivering inaccurate doses. Generics maker Teva ($TEVA) also said it won't be in a position to win approval for its copy until the second half of next year. The result? Open season for Mylan on the epinephrine injection market, of which Bernstein analyst Ronny Gal thinks the company can capture about 95%. More from FiercePharmaMarketing

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.